Background
==========

The common sites of metastasis from colorectal adenocarcinoma are the liver, lung, and regional lymph nodes \[[@B1]\]. Colorectal adenocarcinoma, however, rarely metastasize to the pancreas. Isolated pancreatic metastases from non-pancreatic primary tumors are very rare, accounting for approximately 2% of all pancreatic neoplasms \[[@B2]\]. Renal cell carcinoma is the most common primary malignancy to metastasize to the pancreas \[[@B3]-[@B5]\]. Studies have shown that surgical resections of hepatic or lung metastases for colorectal malignancy patients provide survival benefit \[[@B1]\]. However, the role of surgery for a solitary pancreatic metastasis from colorectal adenocarcinoma has not yet been defined because of the rarity of the condition. To the best of our knowledge, very few colorectal malignancy cases with pancreatic metastases are reported in the literature \[[@B3]-[@B7]\]. Herein, we report a case with primary rectal adenocarcinoma with metachronous pancreatic metastasis undergoing surgical resection and also conduct a substantial review of the literature relevant to pancreatic metastases from colorectal malignancy.

Case Presentation
=================

A 76-year-old Taiwanese woman had undergone neoadjuvant chemotherapy/radiotherapy and abdominoperineal resection for rectal adenocarcinoma (stage IIIa; pT3N0 M0 according to the 6th edition AJCC; Figure [1](#F1){ref-type="fig"}) 2 years ago. No post-operative adjuvant chemotherapy or radiotherapy was administered to the patient. She was relatively well postoperatively, without any evidence of disease recurrence or associated symptoms until she was incidentally found to have a mass in the pancreatic tail on a routine follow up abdominal computed tomography scan.

![**Histological specimen of primary rectal cancer demonstrates a moderately-differentiated adenocarcinoma with invading through the muscularis propria into the subserosa (hematoxylin and eosin staining, 20×)**.](1477-7819-8-26-1){#F1}

On admission, physical examination, hematogram and biochemistry tests were unremarkable, except for a midline operative scar and an end-colostomy. The carcinoembryonic antigen level (2.16 ng/ml) was within normal range. Abdominal computed tomography revealed an ill-defined hypodense mass measuring 3.0 × 1.6 cm in diameter at the pancreatic tail (Figure [2](#F2){ref-type="fig"}). There was no evidence of local recurrence of rectal cancer, lymphadenopathy or distant metastasis. A primary pancreatic malignancy was suspected, and the patient underwent distal pancreatectomy with splenectomy.

![**Abdominal computed tomography reveals an ill-defined hypodense mass approximately 3.0 × 1.6 cm in diameter in the pancreatic tail**.](1477-7819-8-26-2){#F2}

Macroscopically, the cut surface of the pancreatic mass demonstrated a whitish, firm, and infiltrating tumor with ill-defined margins. Histopathological exam showed a moderately differentiated adenocarcinoma with marked necrosis (Figure [3A](#F3){ref-type="fig"}) which was morphologically the same as the primary rectal adenocarcinoma. Immunohistochemical studies showed the tumor cells positive for CK-20 (Figure [3B](#F3){ref-type="fig"}) and CDX-2 (Figure [3C](#F3){ref-type="fig"}), markers for colorectal adenocarcinoma, confirming the final diagnosis of pancreatic metastasis from rectal adenocarcinoma.

![**Photomicrography of the pancreatic mass depicts a moderately differentiated adenocarcinoma with marked necrosis (hematoxylin and eosin staining, 20×;**A). Immunohistochemial stain studies of the pancreatic tumor shows positive for CK-20 (B) and CDX2 (C), further confirming the diagnosis of metastasis from rectal adenocarninoma.](1477-7819-8-26-3){#F3}

The postoperative course was uneventful except for fever which developed 3 weeks after surgery. Abdominal computed tomography revealed a fluid collection, 3 cm in size near the pancreatic stump suggestive of intraabdominal abscess and the patient recovered with antibiotic treatment. Post operative chemotherapy in form of oral capecitabine was given and the patient is alive and disease free 12 months after surgery.

Conclusions
===========

The incidence of pancreatic metastases in autopsy series performed in patients with malignant neoplasms ranged from 1.6-11% \[[@B8]\]. Renal cell carcinoma is the most common primary tumor, followed by lung cancer (adenocarcinoma and non-small cell lung carcinoma), lobular breast carcinoma, and more rarely, gastric cancer, melanoma, and soft-tissue sarcoma \[[@B3],[@B6]-[@B11]\]. Solitary metastases to the pancreas occur even less frequently. Roland *et al*reported that 27 out of 1,357 (2%) non-pancreatic tumor patients had solitary pancreatic metastases, and resections were performed in only 4 patients \[[@B12]\]. Nakeeb *at al*showed that among 363 pancreatoduodenectomies (239 performed for malignant periampullary diseases), metastatic pancreatic tumors were identified in 6 cases (1.65%) \[[@B13]\]. Faure *et al*examined 269 pancreatic resections and found solitary pancreatic metastases in 8 cases (2.97%) \[[@B14]\]. In another study by Sperti *et al*, isolated pancreatic metastases were noted in 8 of 259 pancreatectomies (3%) \[[@B3]\]. Colorectal adenocarcinoma, however, was rarely identified to metastasize to the pancreas in those studies. Table [1](#T1){ref-type="table"} summarizes the details of colorectal adenocarcinoma cases with isolated metastasis to the pancreas in the literature and only 8 rectal adenocarcinoma cases including our patient were identified.

###### 

Clinical data of colorectal cancer patients with isolated pancreatic metastases undergoing pancreatic resection in the literature

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Authors                                Age (years)   Sex   Site of primary tumor   Interval between primary tumor and metastases (months)   Symptoms           Site         Pancreatic surgery   Survival (months)
  -------------------------------------- ------------- ----- ----------------------- -------------------------------------------------------- ------------------ ------------ -------------------- -------------------
  Roland *et al*.\[[@B12]\]              \-            F     Colon                   \-                                                       \-                 Tail         DP                   27 ††

  Nakeeb *et al*.\[[@B13]\]              39            M     Colon                   34                                                       No                 Head         Whipple              43 ††

  Harrison *et al*.\[[@B15]\]            \-            \-    Colon                   15                                                       \-                 Head         Whipple              41 †††

                                         \-            \-    Colon                   15                                                       \-                 Head         Whipple              21 †††

  Inagaki *et al*.\[[@B16]\]             79            M     Rectum                  132                                                      No                 Body-tail    DP                   8 †

  Le Borgne *et al*.\[[@B10]\]           50            M     Colon                   60                                                       Jaundice           Head         Whipple              12 †††

  Tutton *et al*.\[[@B17]\]              37            M     Colon                   23                                                       No                 Tail         DP                   12 †

  Torres-Villalobos *et al*.\[[@B18]\]   86            F     Cecum                   8                                                        Body weight loss   Body-tail-   DP                   6 †

  Crippa *et al*.\[[@B5]\]               50            M     Colon                   7                                                        No                 Head         PPPD                 13 †††

  Matsubara *et al*.\[[@B19]\]           50-           M     Rectum                  36                                                       Jaundice           Head         Whipple              24 †††

  Eidt *et al*.\[[@B20]\]                \-            \-    Colon                   12                                                       \-                 Head         PPPD                 105 †††

  Shimada *et al*.\[[@B21]\]             54            M     Rectum                  44                                                       No                 Head         Whipple              8 †††

  Bachmann *et al*.\[[@B22]\]            61            F     Rectum                  24                                                       Abdominal pain     Tail         DP                   2 †

                                         64            F     Rectum                  30                                                       No                 Body-tail    DP                   10 †

  Reddy *et al*.\*\[[@B4]\]              \-            \-    Colon                   \-                                                       \-                 \-           \-                   3.2 yr\*\*

  Sperti *et al*.\[[@B7]\]               62            M     Colon                   48                                                       Jaundice           Head         Whipple              31 †

                                         71            M     Colon                   0 (synchronous)                                          Jaundice           Head         PPPD                 28 †

                                         59            M     Colon                   10                                                       Jaundice           Head         Whipple              17 †††

                                         62            F     Colon                   36                                                       Abdominal pain     Tail         DP                   14 †

                                         41            F     Colon                   24                                                       Abdominal pain     Head         PPPD                 10 †††

                                         76            F     Colon                   0 (synchronous)                                          Abdominal pain     Head         PPPD                 15 †††

                                         77            F     Colon                   0 (synchronous)                                          No                 Body         DP                   5 †††

                                         48            M     Rectum                  29                                                       No                 Tail         DP                   30 ††

                                         57            M     Rectum                  80                                                       Jaundice           Head\        Enucleation\         24 †††
                                                                                                                                                                 Tail         DP                   

  Present case                           76            F     Rectum                  24                                                       No                 Tail         DP                   12 †
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

-, not available; \*, two cases with colon cancer; \*\*, median cumulative survival of two cases; †, alive; ††; alive with disease;

†††, dead; DP, distal pancreatectomy; PPPD, pylorus-preserving pancreatoduodenectomy

Clinical presentations of colorectal tumor patients with isolated pancreatic metastases are quite different from that of primary pancreatic malignancy patients who frequently have abdominal pain, body weight loss, and jaundice \[[@B7],[@B12]\]. As shown in table [1](#T1){ref-type="table"}, only 4 patients (4/20, 20%) with pancreatic metastases presented abdominal pain and 1 had body weight loss (1/20, 5%). Six of 20 patients (30%) manifested jaundice which might be related to tumor location at the pancreatic head with mass effects \[[@B4],[@B5],[@B7],[@B10],[@B12],[@B13],[@B15]-[@B22]\]. Interestingly, 6 of 11 patients (54.5%) with tumor location at the pancreatic head did not present jaundice. However, it was remarkable that up to 45% of patients (9/20) were asymptomatic upon presentation. It was also reported that imaging studies are unable to differentiate primary pancreatic lesions from metastases by any specific manners \[[@B23],[@B24]\]. These observations and findings suggested that if one had history of a non-pancreatic primary malignancy presenting a pancreatic mass with unusual manifestations during follow-up, solitary pancreatic metastasis, in addition to primary pancreatic malignancy, should be considered.

In regard of treatment of cancer patients with an isolated distant organ metastasis and the absence of widespread diseases, a number of studies have shown that resection of metastases has been proven beneficial for some types of tumors. For example, metastases to the liver, brain, and lung from tumors such as sarcoma, renal cell carcinoma, colorectal cancer, and gastrointestinal stromal tumors, metastasectomy have been reported to have salutary effects on patient survival \[[@B1],[@B25]-[@B28]\]. However the role of surgery for solitary pancreatic metastases from colorectal carcinoma has not yet been well-defined. Given the fact that metastasectomies for colorectal cancer patients with hepatic and pulmonary metastases are beneficial \[[@B1],[@B25]\], it seems to be reasonable to perform pancreatic resections for those patients with isolated pancreatic metastases. Table [1](#T1){ref-type="table"} demonstrated outcomes of patients after pancreatic resections for metastatic colorectal adenocarcinoma with median survival of 16.5 months. Notably, Reddy *et al*reported that a cumulative median survival of patients after pancreatic resection was more than 3 years \[[@B4]\]. In the current case, surgical resection is reasonable to treat and get the definite diagnosis as well as to improve patient survival. Our patient is alive with disease free more than 12 months after distal pancreatectomy and splenectomy. From a review of surgical outcomes of previously reported cases including our patient and less than 5% of surgical mortality rate in pancreatic surgery \[[@B29]\], we suggest that pancreatic resection for a solitary pancreatic metastasis from colorectal carcinoma is safe and feasible in a center with high volume of pancreatic surgery. The role of postoperative adjuvant therapy still remains controversial, and further studies are needed to clarify this issue.

Pancreatic metastases should be kept in mind when a patient with history of a non-pancreatic malignancy, such as colorectal adenocarcinoma presenting a pancreatic mass. Long-term follow-up with appropriate imaging studies is mandatory to detect the distant metastasis including the pancreas. Pancreatic resection for an isolated pancreatic metastasis from colorectal adenocarcinoma is feasible in selected cases. Surgical resection of a solitary pancreatic mass is justified not only to get the definitive diagnosis but also to improve the survival.
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